Skip to main navigation menu Skip to main content Skip to site footer

Vol. 12 No. 11 (2025)
International Multidisciplinary Journal for Research & Development

Articles

METFORMIN AND WEIGHT REDUCTION: A NARRATIVE REVIEW OF CONTEMPORARY EVIDENCE (2024–2025)

Published 2025-11-27

  • Djanayev Gayrat Yusupovich
    • ,
  • Sharipov Akramkhon, Juraev Nabijon, Khodjasheva Saidakhon

Djanayev Gayrat Yusupovich
Scientific supervisor :

Sharipov Akramkhon, Juraev Nabijon, Khodjasheva Saidakhon
Students at Tashkent State Medical University, Tashkent, Uzbekistan

Abstract

Background:
Metformin, the cornerstone therapy for type 2 diabetes mellitus (T2DM), has demonstrated consistent weight-modulating properties beyond its glucose-lowering effects. Recent research (2024–2025) has expanded understanding of its metabolic and hormonal mechanisms influencing adiposity and insulin resistance.

Objective:
This review synthesizes recent randomized controlled trials (RCTs) and meta-analyses examining the efficacy, mechanisms, and safety of metformin in weight reduction among diabetic, prediabetic, and non-diabetic populations.

Methods:
A narrative synthesis was performed using systematic literature searches across PubMed, Scopus, ScienceDirect, and SpringerLink from January 2024 to November 2025. Studies were included if they were peer-reviewed RCTs or quasi-experimental trials evaluating metformin monotherapy or combination therapy for ≥12 weeks, with quantitative outcomes on body weight, BMI, or metabolic parameters. Fifteen studies, encompassing more than 2,000 participants, met inclusion criteria.

Results:
Metformin monotherapy achieved an average weight reduction of 3–5% (≈3.4 kg), while combination therapy with GLP-1 or SGLT2 inhibitors yielded superior outcomes (≈5–7 kg). Mechanistically, metformin activates AMPK, modulates gut microbiota—particularly Akkermansia muciniphila—and influences hypothalamic GLP-1 signaling to enhance satiety and lipid metabolism. The therapy was well tolerated, with gastrointestinal symptoms as the most frequent mild adverse event.

Conclusion:
Metformin remains a safe, cost-effective, and multi-mechanistic pharmacologic option for managing obesity and metabolic disorders. Its synergistic efficacy in combination regimens underscores its evolving role in modern metabolic and precision medicine.

Keywords

Metformin; Weight loss; Obesity; Type 2 diabetes mellitus; PCOS; GLP-1 receptor agonist; SGLT2 inhibitor; AMPK; Gut microbiota; Metabolic regulation.

PDF

References

  1. World Health Organization. Obesity and overweight – Key facts. Geneva: WHO; 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  2. Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular consequences. Circ Res. 2024;135(2):140–156. https://doi.org/10.1161/CIRCRESAHA.123.324567
  3. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2024;67(3):189–203. https://doi.org/10.1007/s00125-023-05903-7
  4. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2024;134(5):e162644. https://doi.org/10.1172/JCI162644
  5. Foretz M, Viollet B. Regulation of hepatic metabolism by AMPK and metformin. J Hepatol. 2025;82(1):234–247. https://doi.org/10.1016/j.jhep.2024.09.011
  6. Malin SK, Kashyap SR. Effects of metformin on weight loss: beyond glucose control. Nat Rev Endocrinol. 2024;20(6):345–358. https://doi.org/10.1038/s41574-024-00981-7
  7. Lee Y, Kim S, Park J. Metformin therapy and long-term weight trajectory: evidence from longitudinal studies. Diabetes Metab J. 2025;49(3):210–222. https://doi.org/10.4093/dmj.2025.0003
  8. Iqbal J, Aziz H, Hussain A. Comparative efficacy of empagliflozin and sitagliptin as adjuncts to metformin in T2DM patients. Prof Med J. 2025;32(4):8585. https://theprofesional.com/index.php/tpmj/article/view/8585
  9. Wu Y, Zhong Y, Tuersun A, Wang Z, Ali SSA. Gut microbiome changes and metabolic outcomes with metformin: a network meta-analysis. SSRN Preprint 5397519. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5397519
  10. Dell’Isola A, Recenti F, Giardulli B, Lawford BJ. Metformin’s role in obesity-related osteoarthritis: therapeutic review. Osteoarthritis Cartilage. 2025;33(8):S1063–4584. https://doi.org/10.1016/j.joca.2025.07.001
  11. Sharif H, Arsalan S, Rehman N, Muzammil A. Comparative effects of empagliflozin and metformin on metabolic dysfunction in PCOS. BMC Women’s Health. 2025;25:4091. https://doi.org/10.1186/s12905-025-04091-6
  12. Hassan S, Sobers NP, Paul-Charles J, Herbert J. Diabetes prevention using lifestyle intervention and metformin escalation (LIME). BMC Public Health. 2025;25:25291. https://doi.org/10.1186/s12889-025-25291-7
  13. Jun JE, Choi SH, Moon MK, Ko SH. Metformin–canagliflozin therapy in uncontrolled diabetes: CANNA trial. Diabetes Obes Metab. 2025;27(3):e1236901. https://pmc.ncbi.nlm.nih.gov/articles/PMC12326901/
  14. Chen H, Lei X, Yang Z, Xu Y, Liu D, Wang C. Metformin and semaglutide combination in overweight PCOS. Reprod Biol Endocrinol. 2025;23(1):1447. https://doi.org/10.1186/s12958-025-01447-3
  15. Sharif H, Arsalan S, Rehman N, Muzammil A. Comparative effects of empagliflozin and metformin on metabolic dysfunction in polycystic ovary syndrome: a double-blind randomized control feasibility trial. BMC Women’s Health. 2025;25:4091. https://doi.org/10.1186/s12905-025-04091-6
  16. Chen H, Lei X, Yang Z, Xu Y, Liu D, Wang C. Effects of metformin and semaglutide combination on weight and metabolic outcomes in overweight women with PCOS: a randomized clinical trial. Reprod Biol Endocrinol. 2025;23(1):1447. https://doi.org/10.1186/s12958-025-01447-3
  17. Jun JE, Choi SH, Moon MK, Ko SH. Efficacy of canagliflozin and metformin combination therapy in uncontrolled type 2 diabetes: the CANNA trial. Diabetes Obes Metab. 2025;27(3):e1236901. https://pmc.ncbi.nlm.nih.gov/articles/PMC12326901/
  18. Hassan S, Sobers NP, Paul-Charles J, Herbert J. Diabetes prevention using lifestyle intervention and metformin escalation (LIME): a quasi-experimental Caribbean study. BMC Public Health. 2025;25:25291. https://doi.org/10.1186/s12889-025-25291-7
  19. Ahsan M, Mallick AK. Efficacy and safety of SGLT2 inhibitors in PCOS: meta-analysis with trial sequential analysis. Indian J Med Res. 2025;161(4):1023–1031.
  20. Wu Y, Zhong Y, Tuersun A, Wang Z. Gut microbiome changes and metabolic outcomes with metformin: a network meta-analysis. SSRN Working Paper 5397519. 2025. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5397519
  21. Dell’Isola A, Recenti F, Giardulli B, Lawford BJ. Metformin’s role in obesity-related osteoarthritis: therapeutic review. Osteoarthritis Cartilage. 2025;33(8):S1063–4584. https://doi.org/10.1016/j.joca.2025.07.001
  22. Hussein DSASA, Kadhim SAA, Swadi AAJ. Coenzyme Q10 and alpha-lipoic acid supplementation with metformin in PCOS: a randomized study. J Obstet Gynecol Clin Res. 2025;45(2):728553.
  23. DelBello MP, Welge JA, Klein CC, Blom TJ. Metformin for overweight and obese children/adolescents treated with antipsychotics: a randomized clinical trial. Lancet Psychiatry. 2025;12(1):e273–9.
  24. Luo Y, Jiang H, Shi B, Cai H, Wang H, Li S. Mazdutide versus semaglutide for obesity: DREAMS-3 Phase 3 trial baseline analysis. Contemp Clin Trials. 2025;134:1551714425003441. https://doi.org/10.1016/j.cct.2025.1551714425003441

Downloads

Download data is not yet available.